{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:32Z","timestamp":1790121632495,"version":"4.0.1"},"reference-count":22,"publisher":"Georg Thieme Verlag KG","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aktuelle Urol"],"abstract":"<jats:title>Zusammenfassung<\/jats:title>\n                  <jats:p>Die Therapieoptionen des metastasierten Nierenzellkarzinoms (mRCC) sind vielf\u00e4ltig. Ziel dieser aktuellen Umfrage der Deutschen Gesellschaft f\u00fcr Immun- und Targeted Therapie e. V. (DGFIT) war es, Daten zur Behandlungsrealit\u00e4t (Real-World Data) des mRCC in Deutschland zu erfassen.<\/jats:p>\n                  <jats:p>Im Zeitraum von August bis September 2023 wurde ein standardisierter Fragebogen \u00fcber E-Mail und QR-Code an Urologen und Onkologen in Deutschland verteilt. Der Fragebogen umfasste 18 Fragen zur initialen Therapie, zur adjuvanten Therapie sowie zur Therapie des mRCC.<\/jats:p>\n                  <jats:p>Insgesamt nahmen 105 \u00c4rzte an der Befragung teil, \u00fcberwiegend Urologen (97%). Eine adjuvante Immuntherapie wird in der Mehrheit der F\u00e4lle regelm\u00e4\u00dfig durchgef\u00fchrt (85%), ebenso erfolgt h\u00e4ufig eine zytoreduktive Nierenchirurgie. Der IMDC-Score wird vor Beginn einer mRCC-Therapie in der Mehrzahl der F\u00e4lle (69,5%) erhoben. Als Erstlinientherapie wird in \u00fcber 70% der F\u00e4lle eine Tyrosinkinase-Inhibitor (TKI) \/ Immuntherapie (IO) Kombination, in 20% eine IO\/IO Kombination und in 6% eine TKI-Monotherapie gew\u00e4hlt. IO\/IO-Kombinationen sowie TKI-Monotherapien werden dabei h\u00e4ufiger in Praxen durchgef\u00fchrt. Nur eine begrenzte Patientenzahl erh\u00e4lt eine Zweitlinientherapie, meist in Form einer TKI-Monotherapie mit Cabozantinib.<\/jats:p>\n                  <jats:p>Mit der vorliegenden Befragung der DGFIT wurden erstmals in Deutschland systematisch Daten zur Behandlungsrealit\u00e4t des mRCC sowie zur Durchf\u00fchrung der adjuvanten Immuntherapie bei Hoch-Risiko RCC nach kurativer Therapie erhoben. Diese Real-World Daten liefern wertvolle Einblicke in die aktuelle Versorgungspraxis und k\u00f6nnen dazu beitragen, bestehende Behandlungspfade weiter zu optimieren und die Therapie der Patienten zu verbessern. Gleichzeitig zeigt sich, dass die Erhebung belastbarer Versorgungsdaten weiterhin eine gro\u00dfe Herausforderung darstellt und zuk\u00fcnftig strukturiert ausgebaut werden sollte.<\/jats:p>","DOI":"10.1055\/a-2940-8196","type":"journal-article","created":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T23:03:16Z","timestamp":1790118196000},"source":"Crossref","is-referenced-by-count":0,"title":["Aktuelle Therapie des metastasierten Nierenzellkarzinoms \u2013 Ergebnisse einer deutschlandweiten Umfrage der Deutschen Gesellschaft f\u00fcr Immun- und Targeted Therapie"],"prefix":"10.1055","author":[{"given":"Axel","family":"Hegele","sequence":"first","affiliation":[{"name":"Urologisches Zentrum Mittelhessen, Germany","place":["Biedenkopf"],"department":["Urologie"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Siebels","sequence":"first","affiliation":[{"name":"Urologie Pasing, Germany","place":["M\u00fcnchen-Pasing"],"department":["Urologie"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Doehn","sequence":"additional","affiliation":[{"name":"Urologikum L\u00fcbeck, Germany","place":["L\u00fcbeck"],"department":["Urologikum L\u00fcbeck"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoltan","family":"Varga","sequence":"additional","affiliation":[{"name":"SRH Krankenhaus Sigmaringen Klinik f\u00fcr Urologie und Kinderurologie, Germany","place":["Sigmaringen"],"department":["Urologie"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Wagner","sequence":"additional","affiliation":[{"name":"UKGM Marburg, Germany","place":["Marburg"],"department":["Gyn\u00e4kologie"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elfriede","family":"Noessner","sequence":"additional","affiliation":[{"name":"Helmholtz Zentrum M\u00fcnchen Institut f\u00fcr Molekulare Immunologie, Germany","place":["M\u00fcnchen"],"department":["Immunoanalytics-Tissue Control Immunocytes"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"H\u00fcbner","sequence":"additional","affiliation":[{"name":"Deutsche Gesellschaft f\u00fcr Immun- und Targeted-Therapie, Germany","place":["M\u00fcnchen"],"department":["DGFIT"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Heinzer","sequence":"additional","affiliation":[{"name":"UKE, Germany","place":["Hamburg"],"department":["Martini-Klinik"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2026,9,22]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s00120-020-01131-x","article-title":"Risk-adapted therapy for metastatic renal cell carcinoma","volume":"59","author":"MO Grimm","year":"2020","journal-title":"Urologe A"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"576","DOI":"10.3238\/arztebl.m2024.0147.","article-title":"The Treatment of Metastatic Renal Cell Carcinoma","volume":"121","author":"P Ivanyi","year":"2024","journal-title":"Dtsch Arztebl Int"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"S0302","DOI":"10.1016\/j.eururo.2025.02.020.","article-title":"European Association of Urology Guidelines on Renal Cell Carcinoma: The 2025 Update","volume":"10","author":"A Bex","year":"2025","journal-title":"Eur Urol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.annonc.2024.05.537.","article-title":"Renal cell carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"35","author":"T Powles","year":"2024","journal-title":"Ann Oncol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1097\/PPO.0000000000000468","article-title":"Prognostic and Predictive Factors in Metastatic Renal Cell Carcinoma: Current Perspective and a Look Into the Future","volume":"26","author":"CL Gan","year":"2020","journal-title":"Cancer J"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1007\/s00120-020-01320-8.","article-title":"Immunotherapy and tyrosine kinase inhibitors in first-line treatment of metastatic renal cell carcinoma-Which strategy when?","volume":"59","author":"G Mickisch","year":"2020","journal-title":"Urologe A"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.euo.2019.06.022.","article-title":"Sequencing and Combination of Systemic Therapy in Metastatic Renal Cell Carcinoma","volume":"2","author":"G de Velasco","year":"2019","journal-title":"Eur Urol Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013773.pub2.","article-title":"Cytoreductive nephrectomy in metastatic renal cell carcinoma","volume":"6","author":"P Dahm","year":"2024","journal-title":"Cochrane Database Syst Rev"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"S229","DOI":"10.1016\/S0007-4551(18)30377-1.","article-title":"Position of cytoreductive nephrectomy in the setting of metastatic renal cell carcinoma patients: does the CARMENA trial lead to a paradigm shift?","volume":"105","author":"C Dariane","year":"2018","journal-title":"Bull Cancer"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1056\/NEJMoa2312695.","article-title":"Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma","volume":"390","author":"TK Choueiri","year":"2024","journal-title":"N Engl J Med"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.eururo.2024.10.019.","article-title":"First and Second-line Treatments in Metastatic Renal Cell Carcinoma","volume":"87","author":"R Barragan-Carrillo","year":"2025","journal-title":"Eur Urol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.euf.2024.08.002.","article-title":"Upfront Versus Deferred Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma: A Systematic Review and Individual Patient Data Meta-analysis","volume":"11","author":"SM Esagian","year":"2025","journal-title":"Eur Urol Focus"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1111\/bju.15625.","article-title":"(2022). Cytoreductive nephrectomy and exposure to sunitinib - a post hoc analysis of the Immediate Surgery or Surgery After Sunitinib Malate in Treating Patients With Metastatic Kidney Cancer (SURTIME) trial","volume":"130","author":"Y Abu-Ghanem","year":"2022","journal-title":"BJU Int"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"5794","DOI":"10.1200\/JCO.2008.21.4809.","article-title":"Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study","volume":"27","author":"DY Heng","year":"2009","journal-title":"J Clin Oncol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1016\/j.annonc.2024.07.727.","article-title":"Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial","volume":"35","author":"NM Tannir","year":"2024","journal-title":"Ann Oncol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1007\/s00262-023-03621-1.","article-title":"Updated systematic review and network meta-analysis of first-line treatments for metastatic renal cell carcinoma with extended follow-up data","volume":"73","author":"T Yanagisawa","year":"2024","journal-title":"Cancer Immunol Immunother"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.21873\/invivo.11422.","article-title":"mRCC Outcome in the Treatment of Metastatic Renal Cell Carcinoma - A German Single-center Real-world Experience","volume":"32","author":"M Schwab","year":"2018","journal-title":"In Vivo"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1200\/JCO.2024.42.16_suppl.4528","article-title":"Comparison of TKI and CPI strategies as first-line treatment of patients with advanced renal cell carcinoma: Real-world outcome data from the German research platform CARAT","volume":"42","author":"PJ Goebell","year":"2024","journal-title":"J Clin Oncol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1002\/phar.70023","article-title":"Belzutifan's role in the treatment landscape of clear cell renal cell carcinoma","volume":"45","author":"AH Chen","year":"2025","journal-title":"Pharmacotherapy"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"LBA418(2026)","DOI":"10.1200\/JCO.2026.44.7_suppl.LBA418","article-title":"Adjuvant pembrolizumab plus belzutifan versus pembrolizumab for clear cell renal cell carcinoma (ccRCC): The randomized phase 3 LITESPARK-022 study","volume":"44","author":"TK Choueiri","year":"2026","journal-title":"J Clin Oncol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1055\/a-2018-9612.","article-title":"Urologische Versorgungsforschung in Deutschland: Auf einem guten Weg!","volume":"54","author":"C Doehn","year":"2023","journal-title":"Aktuelle Urol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1007\/s00120-024-02465-6.","article-title":"Update from d-uo: what can healthcare research contribute to renal cell carcinoma?","volume":"63","author":"M Johannsen","year":"2024","journal-title":"Urologie"}],"container-title":["Aktuelle Urologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2940-8196.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T23:03:18Z","timestamp":1790118198000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2940-8196"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,22]]},"references-count":22,"URL":"https:\/\/doi.org\/10.1055\/a-2940-8196","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0001-7868","1438-8820"],"issn-type":[{"value":"0001-7868","type":"print"},{"value":"1438-8820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,22]]}}}